Literature DB >> 17439988

Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.

Takeshi Matsuoka1, Takuya Matsushita, Yuji Kawano, Manabu Osoegawa, Hirofumi Ochi, Takaaki Ishizu, Motozumi Minohara, Hitoshi Kikuchi, Futoshi Mihara, Yasumasa Ohyagi, Jun-ichi Kira.   

Abstract

Opticospinal multiple sclerosis (OSMS) in Asians has similar features to the relapsing-remitting form of neuromyelitis optica (NMO) seen in Westerners. OSMS is suggested to be NMO based on the frequent detection of specific IgG targeting aquaporin-4 (AQP4), designated NMO-IgG. The present study sought to clarify the significance of anti-AQP4 autoimmunity in the whole spectrum of MS. Sera from 113 consecutive Japanese patients with clinically definite MS, based on the Poser criteria, were assayed for anti-AQP4 antibodies by immunofluorescence using GFP-AQP4 fusion protein-transfected HEK-293T cells. Sensitivity and specificity of the anti-AQP4 antibody assay, 83.3 and 100%, respectively, were calculated using serum samples with NMO-IgG status predetermined at the Mayo Clinic. The anti-AQP4 antibody positivity rate was significantly higher in OSMS patients (13/48, 27.1%) than those with CMS (3/54, 5.6%), other neurological diseases (0/52) or healthy controls (0/35). None of the 11 patients tested with a brainstem-spinal form of MS were positive. Among OSMS patients, the antibody positivity rate was highest in OSMS patients with longitudinally extensive spinal cord lesions (LESCLs) extending over three vertebral segments and brain lesions that fulfilled the Barkhof criteria (5/9, 55.6%). Multiple logistic analyses revealed that emergence of the anti-AQP4 antibody was positively associated only with a higher relapse rate, but not with optic-spinal presentation or LESCLs. Compared with anti-AQP4 antibody-negative CMS patients, anti-AQP4 antibody-positive MS patients showed significantly higher frequencies of severe optic neuritis, acute transverse myelitis and LESCLs while most conditions were also common to anti-AQP4 antibody-negative OSMS patients. The LESCLs in anti-AQP4 antibody-positive patients were located at the upper-to-middle thoracic cord, while those in anti-AQP4 antibody-negative OSMS patients appeared throughout the cervical-to-thoracic cord. On axial planes, the former most frequently showed central grey matter involvement, while holocord involvement was predominant in the latter. In contrast, LESCLs in anti-AQP4 antibody-negative CMS patients preferentially involved the mid-cervical cord presenting a peripheral white matter-predominant pattern, as seen in the short lesions. Anti-AQP4 antibody-positive MS patients fulfilling definite NMO criteria showed female preponderance, higher relapse rate, greater frequency of brain lesions and less frequent responses to interferon beta-1b than anti-AQP4 antibody-negative OSMS patients with LESCLs. These findings suggested that LESCLs are distinct in anti-AQP4 antibody positivity and clinical phenotypes. There were cases of anti-AQP4 antibody-positive MS/NMO distinct from CMS, and anti-AQP4 antibody-negative OSMS with LESCLs in Japanese. This indicated that the mechanisms producing LESCLs are also heterogeneous in cases with optic-spinal presentation, namely AQP4 autoimmunity-related and -unrelated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439988     DOI: 10.1093/brain/awm027

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  57 in total

Review 1.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

2.  Latitude has more significant impact on prevalence of multiple sclerosis than ultraviolet level or sunshine duration in Japanese population.

Authors:  Masako Kinoshita; Kaoru Obata; Masami Tanaka
Journal:  Neurol Sci       Date:  2015-03-10       Impact factor: 3.307

3.  Treatment of neuromyelitis optica: current debate.

Authors:  Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 4.  Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

Authors:  Axel Petzold
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

5.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

6.  Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.

Authors:  Setty M Magaña; Sean J Pittock; Vanda A Lennon; B Mark Keegan; Brian G Weinshenker; Claudia F Lucchinetti
Journal:  Arch Neurol       Date:  2009-08

7.  Evidences for a leaky scanning mechanism for the synthesis of the shorter M23 protein isoform of aquaporin-4: implication in orthogonal array formation and neuromyelitis optica antibody interaction.

Authors:  Andrea Rossi; Francesco Pisani; Grazia Paola Nicchia; Maria Svelto; Antonio Frigeri
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

Review 8.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

9.  Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica.

Authors:  Noriko Isobe; Tomomi Yonekawa; Takuya Matsushita; Katsuhisa Masaki; Satoshi Yoshimura; Jakub Fichna; Shu Chen; Jadwiga Furmaniak; Bernard Rees Smith; Jun-Ichi Kira
Journal:  Neurochem Res       Date:  2013-03-02       Impact factor: 3.996

Review 10.  Immunology of neuromyelitis optica: a T cell-B cell collaboration.

Authors:  Meike Mitsdoerffer; Vijay Kuchroo; Thomas Korn
Journal:  Ann N Y Acad Sci       Date:  2013-04       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.